Small molecule FLT3 tyrosine kinase inhibitors

Mark Levis; Donald Small

doi:10.2174/1381612043452604

Small molecule FLT3 tyrosine kinase inhibitors

Mark Levis, Donald Small

School of Medicine

Research output: Contribution to journal › Review article › peer-review

26 Scopus citations

Abstract

Activating mutations of FLT3 (FMS-Like Tyrosine kinase-3) are the most common molecular abnormality in acute myeloid leukemia (AML). Their presence is associated with a worse prognosis, and the recognition of this has led to the development of several new small molecule FLT3 tyrosine kinase inhibitors. In this review, we summarize these developments and compare and contrast these novel agents both with regards to the assays used to characterize them as well as to their clinical potential.

Original language	English (US)
Pages (from-to)	1183-1193
Number of pages	11
Journal	Current pharmaceutical design
Volume	10
Issue number	11
DOIs	https://doi.org/10.2174/1381612043452604
State	Published - 2004

Keywords

AML
FLT3
Kinase inhibitor
Tyrosine kinase

ASJC Scopus subject areas

Pharmacology
Drug Discovery

Access to Document

10.2174/1381612043452604

Cite this

@article{02a2583a956a48939dc69b73b82ef9b8,

title = "Small molecule FLT3 tyrosine kinase inhibitors",

abstract = "Activating mutations of FLT3 (FMS-Like Tyrosine kinase-3) are the most common molecular abnormality in acute myeloid leukemia (AML). Their presence is associated with a worse prognosis, and the recognition of this has led to the development of several new small molecule FLT3 tyrosine kinase inhibitors. In this review, we summarize these developments and compare and contrast these novel agents both with regards to the assays used to characterize them as well as to their clinical potential.",

keywords = "AML, FLT3, Kinase inhibitor, Tyrosine kinase",

author = "Mark Levis and Donald Small",

year = "2004",

doi = "10.2174/1381612043452604",

language = "English (US)",

volume = "10",

pages = "1183--1193",

journal = "Current pharmaceutical design",

issn = "1381-6128",

publisher = "Bentham Science Publishers B.V.",

number = "11",

}

TY - JOUR

T1 - Small molecule FLT3 tyrosine kinase inhibitors

AU - Levis, Mark

AU - Small, Donald

PY - 2004

Y1 - 2004

N2 - Activating mutations of FLT3 (FMS-Like Tyrosine kinase-3) are the most common molecular abnormality in acute myeloid leukemia (AML). Their presence is associated with a worse prognosis, and the recognition of this has led to the development of several new small molecule FLT3 tyrosine kinase inhibitors. In this review, we summarize these developments and compare and contrast these novel agents both with regards to the assays used to characterize them as well as to their clinical potential.

AB - Activating mutations of FLT3 (FMS-Like Tyrosine kinase-3) are the most common molecular abnormality in acute myeloid leukemia (AML). Their presence is associated with a worse prognosis, and the recognition of this has led to the development of several new small molecule FLT3 tyrosine kinase inhibitors. In this review, we summarize these developments and compare and contrast these novel agents both with regards to the assays used to characterize them as well as to their clinical potential.

KW - AML

KW - FLT3

KW - Kinase inhibitor

KW - Tyrosine kinase

UR - http://www.scopus.com/inward/record.url?scp=1842430924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842430924&partnerID=8YFLogxK

U2 - 10.2174/1381612043452604

DO - 10.2174/1381612043452604

M3 - Review article

C2 - 15078134

AN - SCOPUS:1842430924

SN - 1381-6128

VL - 10

SP - 1183

EP - 1193

JO - Current pharmaceutical design

JF - Current pharmaceutical design

IS - 11

ER -

Small molecule FLT3 tyrosine kinase inhibitors

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this